Exenatide

Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio

Retrieved on: 
Wednesday, February 28, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Exenatide, Injection, Medicine, Multimedia, Semaglutide, Overweight, Obesity, Weight loss, Rat, Patient, Vivani, Human, Mouse, Pharmaceutical industry

NPM-119 has previously demonstrated pharmacokinetic data exhibiting continuous and therapeutic exenatide exposure levels over a six-month duration in healthy rats.

Key Points: 
  • NPM-119 has previously demonstrated pharmacokinetic data exhibiting continuous and therapeutic exenatide exposure levels over a six-month duration in healthy rats.
  • These preclinical data provide further evidence that the weight loss potential of exenatide treatment in humans may be comparable to other GLP-1 molecules such as semaglutide assuming adequate exposure levels are achieved and maintained.
  • NPM-115 is planned to maximize exenatide’s weight loss effect in humans, pending further development and regulatory clearance, by evaluating exenatide exposure levels higher than previously explored.
  • Dr. Mendelsohn will present study results on May 17 at the TIDES USA 2024 conference in Boston.

Orphan designation: exenatide Treatment of moderate and severe closed traumatic brain injury, 20/06/2023 Positive

Retrieved on: 
Sunday, February 4, 2024
COMP, IRIS, European Commission, Consultant, Committee, Patient, Exenatide, EMA, Pharmaceutical industry

Key facts

Key Points: 
  • Key facts
    - Active substance
    - exenatide
    - Intended use
    - Treatment of moderate and severe closed traumatic brain injury
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/23/2793
    - Date of designation
    - Sponsor
    Boyd Consultants Limited
    Patients' organisations
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 November 2023

Retrieved on: 
Monday, December 18, 2023
Medicine, Vomiting, Brain, Liraglutide, European Commission, Pseudoephedrine, Semaglutide, RCVS, PRES, Headache, Dulaglutide, Allergy, Kidney disease, State, EMA, Civil service commission, Signal, Patient, DSM-IV codes, Exenatide, Association, RMP, Vaccine, CHMP, Reversible cerebral vasoconstriction syndrome, Marketing, Data, COVID-19, Seizure, Diagnosis, Communication, Direct, Health care, Review, Failure, PRAC, Confusion, Public, Pharmaceutical industry, Hospital, Dietary supplement, Medical device, Safety

EMA’s safety committee, PRAC, has recommended new measures for medicines containing pseudoephedrine to minimise the risks of posterior reversible encephalopathy syndrome (PRES)…, Agenda Agenda of the PRAC meeting 27-30 November 2023DraftFirst published: 27/11/2023Reference Number: EMA/PRAC/477373/2023…, PRAC statistics: December 2023, Glossary:Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

Key Points: 


EMA’s safety committee, PRAC, has recommended new measures for medicines containing pseudoephedrine to minimise the risks of posterior reversible encephalopathy syndrome (PRES)…, Agenda Agenda of the PRAC meeting 27-30 November 2023DraftFirst published: 27/11/2023Reference Number: EMA/PRAC/477373/2023…, PRAC statistics: December 2023, Glossary:Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

The Evolution of GLP-1s: Overcoming Clinical Development Challenges; Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, October 12, 2023
Type 2 diabetes, Obesity, MD, Critical care, Thermo Fisher Scientific, Diabetes, Metabolism, DSM-IV codes, GIP, NASH, Patient, Fatty liver disease, Clinical trial, PPD, GCG, Research, Comorbidity, Medical device, Pharmaceutical industry, Semaglutide, Exenatide, Pharmacovigilance

TORONTO, Oct. 12, 2023 /PRNewswire-PRWeb/ -- Join us for a comprehensive webinar delving into the latest advancements in novel glucagon-like peptide-1 (GLP-1) receptor agonists in diabetic, obesity and metabolic disease trials. Nearly 20 years after the approval of Exenatide as the first glucagon-like peptide-1 receptor agonist (GLP-1RA) for the treatment of Type 2 Diabetes, the results of recent clinical trials have driven a resurgence in interest in their clinical and off-label use in both diabetic and non-diabetic obese populations.

Key Points: 
  • In this free webinar, learn about the current landscape, latest advancements and common challenges of novel glucagon-like peptide-1 (GLP-1) receptor agonists in diabetic, obesity and metabolic disease trials.
  • TORONTO, Oct. 12, 2023 /PRNewswire-PRWeb/ -- Join us for a comprehensive webinar delving into the latest advancements in novel glucagon-like peptide-1 (GLP-1) receptor agonists in diabetic, obesity and metabolic disease trials.
  • The results of recent clinical trials have driven a resurgence in interest in their clinical and off-label use in both diabetic and non-diabetic obese populations.
  • Further, recent data has shown a decrease in cardiovascular risk in obese, non-diabetic patients treated with Semaglutide.

Oramed Letter to Shareholders

Retrieved on: 
Wednesday, December 21, 2022
Security (finance), Fatty liver disease, TASE, Patient, Absorption, Food, Biotechnology, COVID, Food and Drug Administration, Knowledge, COVID-19, Immunoglobulin G, Diabetes, FDA, Safety, Coronavirus, Completeness, News, Lipid, IND, Pancreas, Type 2 diabetes, Pressure, Seroconversion, Vaccine, Legislation, Letter, Exenatide, Insulin, VLP, Research, NASH, Pharmaceutical industry, Nimesulide, Investment, Oramed

$160 Million in Cash and Investments (as of September 30, 2022)

Key Points: 
  • $160 Million in Cash and Investments (as of September 30, 2022)
    NEW YORK, Dec. 21, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.
  • Dear Shareholders and wider investor community,
    The year 2022 was a very strong year for Oramed.
  • We wish you all a happy and healthy new year and look forward to keeping all our shareholders updated on news and developments.
  • For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed' s reports filed from time to time with the Securities and Exchange Commission.

Adocia announces 2021 fourth quarter financial results

Retrieved on: 
Wednesday, February 23, 2022
IAS, Peptide, Glucagon, Diabetes, Insulin lispro, Industry, Exenatide, Company, IFRS, Safety, Hypoglycemia, Lists of diseases, Protein, Insulin glargine, Obesity, Combo, Patient, Technology, Insulin, Research, Film, Pharmaceutical industry, EUR

The revenue recorded for the year 2021 (EUR 1.4 million) reflects the progress of research and development services provided by Adocia in connection with the transfer and development of products as contracted in 2018.

Key Points: 
  • The revenue recorded for the year 2021 (EUR 1.4 million) reflects the progress of research and development services provided by Adocia in connection with the transfer and development of products as contracted in 2018.
  • The Company had a cash position of EUR 15.2 million as of December 31, 2021, compared to EUR 28.1 million as of December 31, 2020.
  • Cash consumption for the year 2021 amounts to EUR 19.9 million and stands below last year's level (EUR 22.5 million), on a comparable basis (excluding financing operations).
  • Net financial liabilities (excluding derivative debts impacts) amounted to EUR 33.3 million as of December 31, 2021, compared with EUR 27.3 million as of December 31, 2020.

ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of Directors

Retrieved on: 
Wednesday, January 19, 2022
Duke University School of Medicine, Patient, Accounting, Brigham, Associate, Hypoglycemia, LinkedIn, Amylin Pharmaceuticals, SAN, Hypertension, Board of directors, Cell encapsulation, CRISPR Therapeutics, Protein, LLP, W. L. Gore & Associates, Leadership, Virtual College of Biotechnology, University of Saskatchewan, Regenerative medicine, History of the College of William & Mary, View, Duke University Hospital, Industry, Therapy, Brigham and Women's Hospital, Diabetes, Company, Drug development, GlaxoSmithKline Pharmaceuticals Ltd, Hospital, University, Multimedia, Type 2 diabetes, Potency (pharmacology), Risk, PricewaterhouseCoopers, Twitter, College, Senior, Board, Pharmaceutical industry, Management, Exenatide, Facebook, Operation, Endocrinology

"We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte.

Key Points: 
  • "We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte.
  • "I am excited to lead the finance team as we pursue significant clinical and growth opportunities to create increased value across our pipeline."
  • Previously, Ms. Levin was Chief Financial Officer at Bird Rock Bio, a clinical-stage bio-pharmaceutical company focused on the treatment of fibrotic, metabolic and inflammatory diseases.
  • Prior to Nano Precision Medical, Dr. Porter was Chief Medical Officer for Eiger Biopharmaceuticals, Inc. and Dance Biopharma, Inc. (now Aerami Therapeutics).

Adocia announces its financial calendar for 2022

Retrieved on: 
Thursday, January 6, 2022
Safety, Patient, Obesity, Hypoglycemia, Mission statement, Protein, Combo, Lists of diseases, Glucagon, Diabetes, Insulin glargine, Euronext Paris, GLOBE, Exenatide, Technology, ADOC, Peptide, Industry, Insulin, Insulin lispro, Beauty salon, Pharmaceutical industry

LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French socit anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of peptides and proteins, announced today its financial calendar for 2022.

Key Points: 
  • LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French socit anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of peptides and proteins, announced today its financial calendar for 2022.
  • Publication of revenue for Q1 2022.
  • Publication of mid-year financial statements as of June 30, 2022.
  • In addition to regular meetings with the financial community, investors can also find updated information on the companys website ( www.adocia.com ).

Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

Retrieved on: 
Thursday, October 14, 2021
Exenatide, World, Hyperglycemia, Diabetes, Peptide, Program, Euronext Paris, Eli Lilly, Industry, BC, Â, NMPA, Novo Nordisk, Combo, Trial of the century, Protein, National Medical Products Administration, Glycated hemoglobin, Absorption, Lists of diseases, Insulin glargine, ADOC, Patient, Syringe, CDE, Insulin, GLOBE, Center, IQVIA, Company, Hypoglycemia, Glucagon, CEO, Standard of care, Safety, Eli Lilly and Company, Partnership, Center for Drug Evaluation and Research, Obesity, Pharmaceutical industry, Medical device

BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.

Key Points: 
  • BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.
  • For more information on BC Lispro, visit our website: https://www.adocia.com/products/biochaperone-ultra-fast-analog-insulin/
    Adocias partner Tonghua Dongbao is one of the leading insulin providers in Asia.
  • In 2018, Adocia and partner Tonghua Dongbao signed a strategic alliance to develop and commercialize BC Lispro in China and other Asian territories.
  • Tonghua Dongbao also supplies insulin lispro and insulin glargine to Adocia for the worldwide market, except China.

Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

Retrieved on: 
Thursday, October 14, 2021
Exenatide, World, Hyperglycemia, Diabetes, Peptide, Program, Euronext Paris, Eli Lilly, Industry, BC, NMPA, Novo Nordisk, Combo, Trial of the century, Protein, National Medical Products Administration, Glycated hemoglobin, Absorption, Lists of diseases, Insulin glargine, ADOC, Patient, Syringe, CDE, Insulin, GLOBE, Center, IQVIA, Company, Hypoglycemia, Glucagon, CEO, Standard of care, Safety, Eli Lilly and Company, Partnership, Center for Drug Evaluation and Research, Obesity, Pharmaceutical industry, Medical device

BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.

Key Points: 
  • BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin containing insulin lispro and Adocias proprietary technology BioChaperone.
  • For more information on BC Lispro, visit our website: https://www.adocia.com/products/biochaperone-ultra-fast-analog-insulin/
    Adocias partner Tonghua Dongbao is one of leading insulin providers in Asia.
  • In 2018, Adocia and partner Tonghua Dongbao signed a strategic alliance to develop and commercialize BC Lispro in China and other Asian territories.
  • Tonghua Dongbao also supplies insulin lispro and insulin glargine to Adocia for the worldwide market, except China.